Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OVID | Ovid Therapeutics Inc.

IndexRUT P/E- EPS (ttm)-0.70 Insider Own2.50% Shs Outstand70.53M Perf Week-8.31%
Market Cap248.58M Forward P/E- EPS next Y-0.80 Insider Trans0.00% Shs Float55.92M Perf Month-4.71%
Income-49.20M PEG- EPS next Q-0.19 Inst Own53.20% Short Float / Ratio3.72% / 7.22 Perf Quarter-2.41%
Sales0.20M P/S1242.88 EPS this Y-143.70% Inst Trans2.32% Short Interest2.08M Perf Half Y46.77%
Book/sh1.57 P/B2.32 EPS next Y-5.30% ROA-32.80% Target Price5.67 Perf Year89.58%
Cash/sh1.41 P/C2.58 EPS next 5Y- ROE-38.90% 52W Range1.40 - 4.14 Perf YTD95.70%
Dividend- P/FCF- EPS past 5Y25.50% ROI-42.00% 52W High-12.05% Beta1.10
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low159.07% ATR0.24
Employees40 Current Ratio10.10 Sales Q/Q- Oper. Margin- RSI (14)48.76 Volatility7.45% 6.50%
OptionableYes Debt/Eq0.00 EPS Q/Q15.10% Profit Margin- Rel Volume0.38 Prev Close3.61
ShortableYes LT Debt/Eq0.00 EarningsAug 04 BMO Payout- Avg Volume288.29K Price3.64
Recom1.80 SMA20-1.27% SMA501.13% SMA20022.40% Volume108,683 Change0.83%
Date Action Analyst Rating Change Price Target Change
Apr-20-21Downgrade Cantor Fitzgerald Buy → Neutral $4
Mar-03-21Downgrade RBC Capital Mkts Outperform → Sector Perform $5
Dec-02-20Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-02-20Downgrade Citigroup Buy → Neutral $10 → $4
Sep-04-19Initiated RBC Capital Mkts Outperform $12
Apr-20-18Initiated Ladenburg Thalmann Buy $27
Sep-20-23 07:30AM
Aug-30-23 08:00AM
Aug-15-23 09:38PM
Aug-04-23 09:15AM
08:00AM Loading…
Aug-01-23 08:00AM
Jul-31-23 09:29PM
Jul-02-23 10:00AM
Jun-28-23 08:00AM
Jun-26-23 08:00AM
May-22-23 06:43AM
May-05-23 08:45AM
May-01-23 06:00AM
Apr-27-23 02:30PM
12:00PM Loading…
Apr-12-23 12:00PM
Apr-11-23 06:51AM
Apr-10-23 08:00AM
Mar-15-23 06:21AM
Mar-13-23 08:00AM
Mar-09-23 08:00AM
Mar-08-23 08:00AM
Feb-28-23 08:00AM
Feb-08-23 08:00AM
Jan-22-23 07:37AM
Jan-05-23 08:00AM
Dec-02-22 10:00AM
Nov-17-22 07:23AM
Nov-08-22 08:00AM
Oct-18-22 08:57AM
08:00AM Loading…
Sep-27-22 08:00AM
Sep-26-22 09:21AM
Sep-07-22 08:00AM
Aug-14-22 10:40AM
Aug-09-22 08:00AM
Jun-10-22 07:41AM
Jun-06-22 08:00AM
May-11-22 06:55AM
May-10-22 08:00AM
Apr-26-22 07:17AM
Apr-08-22 08:00AM
Mar-15-22 08:00AM
Mar-07-22 01:06PM
Mar-04-22 08:00AM
Feb-28-22 01:51PM
Feb-08-22 08:00AM
Jan-04-22 08:01AM
Jan-03-22 07:25AM
Nov-10-21 08:30AM
Nov-05-21 12:03PM
Oct-07-21 08:30AM
Sep-07-21 08:00AM
Sep-06-21 12:58PM
Aug-16-21 08:00AM
Jul-08-21 04:30PM
Jul-07-21 08:00AM
Jul-06-21 07:01AM
Jun-04-21 08:00AM
May-26-21 08:00AM
May-24-21 07:52AM
May-21-21 08:46AM
May-20-21 09:29AM
May-13-21 04:05PM
May-12-21 08:00AM
May-07-21 08:42AM
Apr-30-21 11:37AM
Apr-20-21 08:00AM
Apr-19-21 09:16AM
Mar-30-21 08:00AM
Mar-20-21 04:51AM
Mar-16-21 08:39AM
Mar-15-21 08:00AM
Mar-10-21 03:44AM
Mar-03-21 07:46AM
Jan-15-21 02:22AM
Dec-16-20 07:00AM
Dec-02-20 11:38AM
Dec-01-20 04:52PM
Nov-25-20 08:51AM
Nov-23-20 04:01PM
Nov-16-20 06:07AM
Nov-12-20 04:10PM
Oct-14-20 07:00AM
Oct-12-20 07:00AM
Oct-05-20 05:30AM
Sep-30-20 08:00AM
Sep-11-20 08:00AM
Aug-25-20 07:50AM
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, currently under preclinical stage, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825, currently under preclinical stage, which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, currently under preclinical stage, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.